Anda di halaman 1dari 1

Federal Register / Vol. 72, No.

166 / Tuesday, August 28, 2007 / Notices 49285

are risk factors for infertility, the DEPARTMENT OF HEALTH AND notify the Contact Person listed below
transmission of HIV, and human HUMAN SERVICES in advance of the meeting.
papilloma virus-induced cervical A portion of the meeting will be
neoplasia. Control of C. trachomatis National Institutes of Health closed to the public in accordance with
infections is an important public health the provisions set forth in sections
goal. Unexpectedly, however, aggressive Clinical Center; Notice of Closed 552b(c)(4) and 552b(c)(6), as amended.
infection control measures based on Meeting The grant applications and the
early detection and antibiotic treatment discussions could disclose confidential
Pursuant to section 10(d) of the
have resulted in an increase in infection trade secrets or commercial property
Federal Advisory Committee Act, as
rates, most likely by interfering with such as patentable material, and
amended (5 U.S.C. Appendix 2), notice
natural immunity, a concept suggested personal information concerning
is hereby given of a meeting of the
by studies performed in experimental individuals associated with the grant
Board of Scientific Counselors of the
infection models. Effective management applications, the disclosure of which
NIH Clinical Center.
of chlamydial disease will likely require would constitute a clearly unwarranted
The meeting will be closed to the
the development of an efficacious invasion of personal privacy.
public as indicated below in accordance
vaccine. with the provisions set forth in section Name of Committee: National Cancer
This technology claims vaccine Advisory Board.
552b(c)(6), Title 5 U.S.C., as amended
compositions that comprise an Open: September 17, 2007, 8:30 a.m. to
for the review, discussion, and 4:15 p.m.
immunologically effective amount of
evaluation of individual intramural Agenda: Program reports and
PmpD protein from C. trachomatis. Also
programs and projects conducted by the presentations; Business of the Board.
claimed in the application are methods
Clinical Center, including consideration Place: National Cancer Institute, 9000
of immunizing individuals against C.
of personnel qualifications and Rockville Pike, Building 31, C Wing, 6th
trachomatis. PmpD is an antigenically Floor, Conference Room 10, Bethesda, MD
performance, and the competence of
stable pan-neutralizing target that, in 20892.
individual investigators, the disclosure
theory, would provide protection Contact Person: Dr. Paulette S. Gray,
of which constitute a clearly
against all human strains, thus allowing Executive Secretary, National Cancer
unwarranted invasion of personal Institute, National Institutes of Health, 6116
the development of a univalent vaccine
privacy. Executive Boulevard, 8th Floor, Room 8001,
that is efficacious against both blinding
trachoma and sexually transmitted Name of Committee: Board of Scientific Bethesda, MD 20892–8327, (301) 496–5147.
disease. Counselors of the NIH Clinical Center. Name of Committee: National Cancer
Application: Prophylactics against C. Date: September 24–25, 2007. Advisory Board.
Time: 8 a.m. to 12 p.m. Closed: September 17, 2007, 4:15 p.m. to
trachomatis. Agenda: To review and evaluate the 5:30 p.m.
Developmental Status: Preclinical Critical Care Medicine Program. Agenda: Review of grant applications.
studies have been performed. Place: National Institutes of Health, Contact Person: Dr. Paulette S. Gray,
Inventors: Harlan Caldwell and Building 10, 10 Center Drive, CRC Room 4– Executive Secretary, National Cancer
Deborah Crane (NIAID). 2551, Bethesda, MD 20892. Institute, National Institutes of Health, 6116
Publication: DD Crane et al. Contact Person: David K. Henderson, MD, Executive Boulevard, 8th Floor, Room 8001,
Chlamydia trachomatis polymorphic Deputy Director for Clinical Care, Office of Bethesda, MD 20892–8327, (301) 496–5147.
membrane protein D is a species- the Director, Clinical Center, National Name of Committee: National Cancer
common pan-neutralizing antigen. Proc. Institutes of Health, Building 10, Room 6– Advisory Board.
Natl Acad Sci USA. 2006 Feb 1480, Bethesda, MD 20892, (301) 496–3515. Open: September 18, 2007, 8 a.m. to 12
7;103(6):1894–1899. Epub 2006 Jan 30. Dated: August 20, 2007. p.m.
Patent Status: PCT Patent Application Agenda: Program reports and
Jennifer Spaeth,
presentations; Business of the Board.
No. PCT/US2007/001213 filed 16 Jan Director, Office of Federal Advisory Contact Person: Dr. Paulette S. Gray,
2007 (HHS Reference No. E–031–2006/ Committee Policy. Executive Secretary, National Cancer
0–PCT–02). [FR Doc. 07–4196 Filed 8–27–07; 8:45 am] Institute, National Institutes of Health, 6116
Licensing Status: Available for BILLING CODE 4140–01–M Executive Boulevard, 8th Floor, Room 8001,
exclusive or non-exclusive licensing. Bethesda, MD 20892–8327, (301) 496–5147.
Licensing Contact: Peter A. Soukas, Any interested person may file written
J.D.; 301/435–4646; DEPARTMENT OF HEALTH AND comments with the committee by forwarding
soukasp@mail.nih.gov. the statement to the Contact Person listed on
HUMAN SERVICES this notice. The statement should include the
Collaborative Research Opportunity:
name, address, telephone number and when
The NIAID, Laboratory of Intracellular National Institutes of Health applicable, the business or professional
Parasites, is seeking statements of affiliation of the interested person.
capability or interest from parties National Cancer Institute; Notice of In the interest of security, NIH has
interested in collaborative research to Meeting instituted stringent procedures for entrance
further develop, evaluate, or Pursuant to section 10(d) of the
onto the NIH campus. All visitor vehicles,
commercialize PmpD vaccine including taxicabs, hotel, and airport shuttles
Federal Advisory Committee Act, as will be inspected before being allowed on
development. Please contact Harlan D. amended (5 U.S.C. Appendix 2), notice
Caldwell, at hcaldwell@niaid.nih.gov or campus. Visitors will be asked to show one
is hereby given of the meeting of the form of identification (for example, a
406/363–9333 for more information. National Cancer Advisory Board. government-issued photo ID, driver’s license,
Dated: August 21, 2007. The meeting will be open to the or passport) and to state the purpose of their
Steven M. Ferguson, public as indicated below, with visit.
pwalker on PROD1PC71 with NOTICES

Information is also available on the


Director, Division of Technology Development attendance limited to space available. Institute’s/Center’s home page:
and Transfer, Office of Technology Transfer, Individuals who plan to attend and deainfo.nci.nih.gov/advisory/ncab.htm,
National Institutes of Health. need special assistance, such as sign where an agenda and any additional
[FR Doc. E7–16935 Filed 8–27–07; 8:45 am] language interpretation or other information for the meeting will be posted
BILLING CODE 4140–01–P reasonable accommodations, should when available.

VerDate Aug<31>2005 19:52 Aug 27, 2007 Jkt 211001 PO 00000 Frm 00039 Fmt 4703 Sfmt 4703 E:\FR\FM\28AUN1.SGM 28AUN1